Could a single stem cell shot ease arthritic knees?
NCT ID NCT07106229
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tests whether a single injection of MAG200 stem cells can improve pain and daily function in adults with knee osteoarthritis. About 573 participants will receive either a low dose, a high dose, or a placebo injection. The study aims to confirm if this approach offers a meaningful benefit over placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MAG200 (allogeneic adipose-derived mesenchymal stem cells)
What this could lead to
If it works, this could provide a new, single-injection treatment to reduce pain and improve daily function for people with knee osteoarthritis.
What could go wrong
This is a large Phase 3 trial, but stem cell treatments for osteoarthritis have had mixed results in earlier studies. The effect may be modest, and long-term safety is still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRISTIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••